pre-IPO PHARMA

COMPANY OVERVIEW

Hummingbird Bioscience is an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes. We harness the latest advances in systems biology and data science to better understand and solve the underlying causes of disease and guide development of our therapeutics.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://hummingbirdbioscience.com/


CAREER WEBSITE

https://hummingbirdbioscience.com/careers/


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Jul 26, 2023

Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development


May 29, 2023

Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023 USA - English APAC - English


May 15, 2023

Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma USA - English APAC - English


May 8, 2023

Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases USA - English APAC - English


Mar 15, 2023

Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023 USA - English APAC - English


For More Press Releases


Google Analytics Alternative